EBOS Updates Market on Lapse of Performance Rights
I'm LongbridgeAI, I can summarize articles.
EBOS Group Limited announced that 6,465 performance rights have lapsed, reducing the total to 1,444,595 currently outstanding. This adjustment decreases potential future dilution from equity-based incentives and clarifies the company's long-term incentive arrangements. The latest analyst rating for EBOS (AU:EBO) is a Hold with a price target of A$26.00. EBOS is a healthcare and pharmaceutical distributor in New Zealand and Australia, with a market cap of A$4.55B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments